Aurobindo Pharma Eyes Massive Zentiva Buyout, Sees Shares Dip 5% Amid Deal Buzz

Hey, did you hear about what’s happening with Aurobindo Pharma?

Today, on August 20, their stock price dropped almost 5% to ₹1,039.

The quesion arises why? It is because the reports suggest that they’re about to buy Zentiva. 

Zentiva is a big medicine company from Prague. The speculations about this deal is making the buzz interesting. If done and dealed succesfully, this deal is huge, it could be worth around $5 to $5.5 billion (that’s over ₹43,000 crore!).

If it goes through, it would be the biggest takeover ever by an Indian pharma company, whether in India or abroad. And that is why this news is grabbing headline. The concern here is, even after such big buyout, why are the shares of the company trumbling down. 

And why should investors care about this?

Zentiva is a major player in Europe’s medicine market. Buying them could really help Aurobindo grow bigger and stronger globally. But, some investors are a bit nervous because this is a massive deal and might come with risks. What do you think? Is this a smart move for Aurobindo’s future? We’ll just have to wait and see!

How The Zentiva Deal Could Change Aurobindo Pharma

• If completed, this deal would be bigger than past major pharma acquisitions like:
  • Daiichi Sankyo’s $3.2 billion purchase of Ranbaxy in 2014
  • Biocon Biologics’ $3.3 billion cash-and-stock deal for Viatris’ biosimilars business
• The acquisition would boost Aurobindo’s presence in Europe, especially in Eastern European countries
• Key markets include the Czech Republic, Romania, and Slovakia
• These regions are seen as high-growth areas for biosimilars
• Growth potential is driven by the expiry of patents on major prescription drugs

So, what did Aurobindo Pharma say about all these reports?

As said earlier, the reprots were based on speculation and the cpmany had to respind to teh public about the deal. 

The company responded with an official statement, saying they often look for new opportunities like acquisitions and partnerships to grow and benefit their shareholders. But here’s the important part, they made it clear that no final deal or agreement has been approved by their board yet.

They also asked everyone not to take the news as confirmed just yet because it’s still early and nothing is set in stone. Aurobindo promised that if anything important happens that needs to be shared, they’ll inform the stock exchanges right away, following all the rules.

So, for now, it’s a wait-and-watch situation! 

Aurobindo Pharma Q1 Performance And Stock Update

• Net Profit: ₹824 crore in Q1 FY26, down 10.2% from ₹918 crore in Q1 FY25
• Revenue: Increased 4% to ₹7,868 crore from ₹7,567 crore year-on-year
• Operating EBITDA: ₹1,603 crore, slightly lower than ₹1,619.6 crore last year
• EBITDA Margin: Dropped to 20.4% from 21.4% in Q1 FY25
• US Formulations Revenue: Fell 1.9% to ₹3,488 crore ($408 million) due to destocking and seasonal factors
• European Formulations Revenue: Grew strongly by 18% to ₹2,338 crore
• Stock Trend: Shares dropped 4.7% to an intraday low of ₹1,039.30
• 12-Month Performance: Shares declined over 28%, with a 22% fall so far in 2025

(With Inputs From Sources And Official Statement)

Also Read: Gold, Bitcoin Emerge As Top-Performing Assets In 2025, Outpacing Equities And Bonds -Check Full Details